BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT

Reuters

28 Mar

BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT

March 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:

FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT
MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY
MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED
MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES
MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING

Source text: ID:nGNXZV9tl

Further company coverage: MIST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522578087"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522578087\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522578087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522578087","market":"us","top_or_hot":-1,"title":"BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>Milestone Pharmaceuticals Inc <span>MIST.O</span>:</p><ul><li><p>FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT</p></li><li><p>MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY</p></li><li><p>MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED</p></li><li><p>MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES</p></li><li><p>MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING</p></li></ul><p>Source text: <span>ID:nGNXZV9tl</span></p><p>Further company coverage: <span>MIST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-28 19:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>Milestone Pharmaceuticals Inc <span>MIST.O</span>:</p><ul><li><p>FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT</p></li><li><p>MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY</p></li><li><p>MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED</p></li><li><p>MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES</p></li><li><p>MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING</p></li></ul><p>Source text: <span>ID:nGNXZV9tl</span></p><p>Further company coverage: <span>MIST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIST","symbol_name":"Milestone Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA2SXRZ8:1","article_id":"2522578087","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522578087","pubTimestamp":1743162834,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVTMarch 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVTMILESTONE PHARMACEUT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIST":"Milestone Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"简报-FDA发布了Etripamil治疗PSVT的完整回复函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":0.9},"content_text":"BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVTMarch 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVTMILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACYMILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISEDMILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIESMILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTINGSource text: ID:nGNXZV9tlFurther company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}